The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.
The study hypothesis is that when used as an anticoagulant in haemofiltration, fondaparinux prolongs the filter life when compared to enoxaparin. Fondaparinux is the first compound of a new class of synthetic oligosaccharides with antithrombotic effects. It represents the active portion of the natural heparin molecule. The null hypothesis is that there is no difference in filter life when using fondaparinux or enoxaparin as anticoagulation for haemofiltration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
The Royal Melbourne Hospital Intensive Care Unit Grattan Street
Parkville, Victoria, Australia
The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.
Time frame: Duration of the haemofilter life
To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.
Time frame: Until hospital discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.